Pirüvat dehidrojenaz enzim kompleksinin epitelyal mezenkimal dönüşüm ile ilişkisinin in vitro araştırılması
Year: 2018
Type: dissertation
Abstract: Recently, mitochondria have attracted much attention in metastatic cancer research. There are several reports showing that highly metastatic cancer cells preferentially use glycolysis over mitochondrial respiration for energy production. Pyruvate dehydrogenase enzyme complex (PDH), the gatekeeper enzyme of mitochondria is shown to be responsible for this switch in some cancers. Epithelial mesenchymal transition (EMT), has been proposed to be a driving force of metastasis. In this study, the existence of a link between EMT and cancer cell metabolism has been investigated. To inhibit PDH activity, pharmacological (PDH inhibitor, Cpi-613) and RNAi (stable cell lines were established by lentivirus) were used in A-549 cells. The antiproliferative effect of Cpi-613 was investigated by xCELLigence System, SRB and ATP viability assays. Wound healing, invasion and drug sensitivity tests were applied at antiproliferative doses. To demonstrate the EMT phenotype in cells, the expression of EMT-related proteins were analyzed via western blotting. Furhermore, SB-431542 (TGF-β receptor inhibitor) was used to test whether Cpi-613 induced EMT depends on TGF-β signalling. As a result both the inhibition of PDH by Cpi-613 and the knockdown of PDHA1 induced morphological changes, which were characteristics of EMT. A more rapid wound healing, increased invasive potential and chemoresistance were also shown. SB-431542 treatment reversed the EMT phenotype. The proportion of CD133+ (a cancer stem cell marker) cells were also higher in shPDHA1 cells than those of shControl cells. In brief, knockdown of PDHA1 expression or inhibition of PDH activity induced the EMT phenotype and more importantly resulted in resistance to chemotherapeutic drugs. Therefore, the use of Cpi- 613 or PDH blockers becomes debatable for use in anticancer therapy. Keywords: Lung cancer, epithelial mesenchymal transition, drug resistance, cancer cell
Source: Bursa Uludag University - AVESIS
Author: Buse Cevatemre
Institution: Bursa Uludağ Üni̇versi̇tesi̇
Language: Turkish
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W3092107644
